WuXi Biologics will be attending
BIO International 2019

Click Here to Schedule a Meeting
WuXi Biologics Successfully Completed First FDA Routine GMP Inspection

WuXi Biologics to be the first biologics company in China approved by both the U.S. FDA and EMA

WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu

WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity
WuXi Biologics and I-Mab Biopharma Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

WuXi Biologics and NBE-Therapeutics announce comprehensive ADC development and manufacturing partnership

ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Novel Immune Check Point Bispecifics for $220 Million

WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA
See a presentation about our WuXiBody bispecific antibody platform at these events (Click below for details)

June 11-13, 2019
June 18-20, 2019
August 5-9, 2019
WuXi Biologics wins 2019 CMO Leadership Awards in all six core categories

WuXi Biologics receive's "Asia's Best CMO of 2018" award from IMAPAC